Safety assessment of a proprietary fenugreek mucilage composition (FenuMat®): Acute and subchronic toxicity studies

Fenugreek ( Trigonella foenum-graecum ) seeds and their extracts are popular culinary ingredients and nutraceuticals. The seed mucilage contains galactomannan, a soluble dietary fiber with prebiotic potential and divergent therapeutic effects. A proprietary fenugreek galactomannan preparation (F-GM), FenuMat®, functions as a natural self-emulsifying hydrogel, enhancing nutrient delivery and bioavailability. Although fenugreek seed safety is well documented, the safety evaluation of FenuMat® is warranted to ensure its compliance with regulatory standards. Hence, the present study evaluated the safety of FenuMat® in adult Wistar rats of both sexes, following OECD guidelines. In the acute oral toxicity study (14 days; OECD Guideline 423), no treatment related adversities were observed, indicating an LD₅₀ above 2000 mg/kg body weight. The subchronic toxicity study (OECD Guideline 408, repeated dose; 90 days) at doses of 250, 500 and 1000 mg/kg b.wt. revealed no significant alterations in hematological or biochemical parameters, or in food and water intake. However, significant reductions in serum glucose levels (at 500 mg/kg and 1000 mg/kg b.wt.) and LDL cholesterol levels (at 1000 mg/kg b.wt.) were observed. Histopathological evaluation revealed no morphological abnormalities in the major organs. Terminal autopsy revealed consistent relative organ weights and no treatment-related histopathological alterations. The high-dose recovery group (1000 mg/kg b.wt.) exhibited no mortality or adverse effects, with hematological and biochemical parameters comparable to controls, indicating a no-observed-adverse-effect level (NOAEL) of 1000 mg/kg b.wt. Further, the Ames test on four Salmonella triphimurium strains, with and without metabolic activation, demonstrated no mutagenic potential, indicating FenuMat®’s suitability for human use. • Fenugreek seed mucilage (galactomannan) as a ‘self-emulsifying natural hydrogel’ (FenuMat®). • Fenugreek galactomannan (F-GM) is a debitterized soluble dietary fiber. • Acute toxicity study indicated the safety of F-GM with an LD 50 as > 2000 mg/kg body weight. • Sub-chronic toxicity study did not show any toxicity and indicated NOAEL as 1000 mg/kg body weight. • Genotoxicity studies indicated the non-mutagenicity of F-GM.

Authors

Publication Details

Journal
Toxicology Reports
Published
2025-12-19
DOI
https://doi.org/10.1016/j.toxrep.2025.102187
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety assessment of a proprietary fenugreek mucilage composition (FenuMat®): Acute and subchronic toxicity studies

Krishnakumar Illathu Madhavamenon, Robin Cherian, Kanjoormana Aryan Manu, Mani Ganesh et al.
Toxicology Reports
Natural Antidiabetic Agents Studies
article

Safety assessment of a proprietary fenugreek mucilage composition (FenuMat®): Acute and subchronic toxicity studies

Krishnakumar Illathu Madhavamenon, Robin Cherian, Kanjoormana Aryan Manu, Mani Ganesh, Syam Das S
article en

Abstract

Fenugreek ( Trigonella foenum-graecum ) seeds and their extracts are popular culinary ingredients and nutraceuticals. The seed mucilage contains galactomannan, a soluble dietary fiber with prebiotic potential and divergent therapeutic effects. A proprietary fenugreek galactomannan preparation (F-GM), FenuMat®, functions as a natural self-emulsifying hydrogel, enhancing nutrient delivery and bioavailability. Although fenugreek seed safety is well documented, the safety evaluation of FenuMat® is warranted to ensure its compliance with regulatory standards. Hence, the present study evaluated the safety of FenuMat® in adult Wistar rats of both sexes, following OECD guidelines. In the acute oral toxicity study (14 days; OECD Guideline 423), no treatment related adversities were observed, indicating an LD₅₀ above 2000 mg/kg body weight. The subchronic toxicity study (OECD Guideline 408, repeated dose; 90 days) at doses of 250, 500 and 1000 mg/kg b.wt. revealed no significant alterations in hematological or biochemical parameters, or in food and water intake. However, significant reductions in serum glucose levels (at 500 mg/kg and 1000 mg/kg b.wt.) and LDL cholesterol levels (at 1000 mg/kg b.wt.) were observed. Histopathological evaluation revealed no morphological abnormalities in the major organs. Terminal autopsy revealed consistent relative organ weights and no treatment-related histopathological alterations. The high-dose recovery group (1000 mg/kg b.wt.) exhibited no mortality or adverse effects, with hematological and biochemical parameters comparable to controls, indicating a no-observed-adverse-effect level (NOAEL) of 1000 mg/kg b.wt. Further, the Ames test on four Salmonella triphimurium strains, with and without metabolic activation, demonstrated no mutagenic potential, indicating FenuMat®’s suitability for human use. • Fenugreek seed mucilage (galactomannan) as a ‘self-emulsifying natural hydrogel’ (FenuMat®). • Fenugreek galactomannan (F-GM) is a debitterized soluble dietary fiber. • Acute toxicity study indicated the safety of F-GM with an LD 50 as > 2000 mg/kg body weight. • Sub-chronic toxicity study did not show any toxicity and indicated NOAEL as 1000 mg/kg body weight. • Genotoxicity studies indicated the non-mutagenicity of F-GM.

Toxicology ReportsVol. 16
Openalex Percentile: Top 46%
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.